IDEXX Q4 revenue +7% organic; EPS $2.05; FY23 guidance rev $3.59B-$3.69B, EPS $9.27-$9.75

IDEXX LABORATORIES INC /DE

2022-FY EPS reported $8.03 revenue$3,367,324,000

Q4 revenue $829M (+3% reported, +7% organic); EPS $2.05 (+8% reported, +14% comparable).
FY2022 revenue $3,367M (+5% reported, +7% organic); EPS $8.03 (-7% reported, -1% comparable, including discrete R&D headwind).
CAG Diagnostics recurring revenue grew 4% reported, 8% organic in Q4; global premium instrument installed base up 13% YoY.
FY2023 guidance: revenue $3.59B-$3.69B (6.5%-9.5% reported growth); EPS $9.27-$9.75 (16%-21% reported growth).
Q4 operating margin 27.3% (+240bps reported); 2023 operating margin target 29.0%-29.6%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2022 guidance (initiated).

Period: the quarter and year ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

IDEXX LABORATORIES INC /DE filing history →

Source: SEC EDGAR

accession 0000950170-23-001820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.